Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 111 (E3 ubiquitin-protein ligase Arkadia) is a nuclear enzyme containing a RING finger domain, operating as an E3 ubiquitin ligase. It promotes the ubiquitination and proteasomal degradation of negative regulators of the TGF-beta/Nodal pathway, such as Smad7, c-Ski, and SnoN, enhancing transcriptional activation and facilitating embryonic development, hematopoietic stem/progenitor cell maintenance, and cellular responses to DNA damage. Arkadia also acts as a SUMO-targeted ubiquitin ligase (STUbL), targeting polysumoylated proteins for degradation, with important functions in tissue fibrosis, cancer progression, and hematopoiesis. Dysfunction or altered regulation of RNF111 may contribute to cancer, fibrotic disease, hematological defects, and impaired DNA repair.
Drugs targeting RNF111/Arkadia would typically act via inhibition of E3 ligase activity, modulating ubiquitination, proteasomal degradation, altering TGF-beta/Nodal signaling, or impacting SUMO-mediated protein turnover
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase Arkadia (RNF111).